MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Lantheus Holdings, Inc. (NASDAQ: LNTH)*
Organization & Developments: Lantheus
Parents
Lantheus Holdings, Inc. (NASDAQ: LNTH)*
Children
*Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide.
*The company operates primarily in the radiopharmaceutical industry, offering products such as Neuraceq, a PET imaging agent used to detect beta-amyloid plaques in patients with cognitive impairment, including Alzheimer’s disease.
2021: FDA approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.
2021: Lantheus gets FDA nod for Pylarify PET agent for prostate cancer
2022: A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock
2022: Injectable imaging agent, Pylarify helps doctors to locate prostate cancer under organ imaging known as a PET scan.
2022: Lantheus Holdings: May Be Time To Buy After Big Correction_ seekingalpha.com
2022: Lantheus: Managing A Winner_seekingalpha.com
2022: Looking In On Lantheus Holdings_seekingalpha.com
2022: Pylarify AI is an FDA-cleared artificial intelligence platform that assists in standardized quantification of the Pylarify injection in PET and CT scans.
2022: Radiopharm collaborates with Lantheus on theranostic agent
2022: Widely seen as a first-of-its-kind diagnostic tool, offering major advantages over conventional CT scans, bone scans and magnetic resonance imaging, or MRI scans.
2023: Lantheus Holdings: Building A Sales Juggernaut_ seekingalpha.com
2023: Lantheus Stock: Looking To Add After SPLASH's Belly-Flop_ seekingalpha.com
2023: Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment_ seekingalpha.com
2024: Lantheus Holdings (LNTH): A Radiopharmaceutical Leader with Strong Q2 2024 Growth
2024: Lantheus Holdings: Powerhouse Potential In 2025
2024: Lantheus Holdings: Q3 Results Were Good But Market Overreacted
2024: Lantheus Holdings: Undervalued With A Good Outloo
2024: We Ran A Stock Scan For Earnings Growth And Lantheus Holdings (NASDAQ:LNTH) Passed With Ease
2025: Lantheus announces plans to divest SPECT imaging business
2025: Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy
2025: Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Jumps
Finance & Acquisitions: Lantheus
Key People: Lantheus